6měsíční a 18měsíční randomizovaná duální studie hodnotící bezpečnost a účinnost Buntanetapu u účastníků s časnou AD (DUET-AD)
6měsíční a 18měsíční prospektivní, randomizovaná, placebem kontrolovaná, dvojitě zaslepená duální klinická studie zkoumající účinnost a bezpečnost Buntanetapu při léčbě účastníků časné Alzheimerovy choroby
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
- Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
- Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
- What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.
Participants will:
- Take buntanetap/Posiphen or a placebo every day for 18 months
- Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
- Complete pre- and post-clinic visit phone calls
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Arizona
-
Chandler, Arizona, Spojené státy, 85286
- MD First Research
-
Phoenix, Arizona, Spojené státy, 85004
- Xenoscience
-
Scottsdale, Arizona, Spojené státy, 85258
- Clinical Endpoints
-
-
California
-
Anaheim, California, Spojené státy, 92805
- Advanced Research Center
-
Canoga Park, California, Spojené státy, 91303
- Hope Clinical Research
-
Imperial, California, Spojené státy, 92251
- Sun Valley Research
-
Los Angeles, California, Spojené státy, 90095
- Mary S. Easton Center for Alzheimer's Research and Care, UCLA
-
Sacramento, California, Spojené státy, 95816
- UC Davis Alzheimer's Disease Research Center
-
San Marcos, California, Spojené státy, 92069
- The Neuron Clinic
-
-
Colorado
-
Basalt, Colorado, Spojené státy, 81621
- Mountain Neurological Center
-
Englewood, Colorado, Spojené státy, 80113
- CenExel Rocky Mountain
-
-
Connecticut
-
Norwalk, Connecticut, Spojené státy, 06851
- Research Center for Clinical Trials
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- Visionary Investigators Network
-
Boca Raton, Florida, Spojené státy, 33487
- SFM Clinical Research
-
Clermont, Florida, Spojené státy, 34711
- K2 Medical Research
-
Daytona Beach, Florida, Spojené státy, 32114
- K2 Medical Research Daytona
-
Fort Myers, Florida, Spojené státy, 33912
- Neuropsychiatric Research Center
-
Hallandale, Florida, Spojené státy, 33009
- Velocity Clinical
-
Jacksonville, Florida, Spojené státy, 32216
- Jacksonville Center for Clinical Research
-
Lady Lake, Florida, Spojené státy, 32159
- K2 Medical Research
-
Lake Worth, Florida, Spojené státy, 33462
- Headlands Research JEM
-
Lakeland, Florida, Spojené státy, 33803
- Accel Research Sites Lakeland (Alcanza)
-
Maitland, Florida, Spojené státy, 32751
- K2 Medical Research
-
Melbourne, Florida, Spojené státy, 32940
- ClinCloud Clinical Research
-
Merritt Island, Florida, Spojené státy, 32952
- Flourish Research/Merritt Island Medical Research
-
Miami, Florida, Spojené státy, 33137
- Miami Jewish Health
-
Naples, Florida, Spojené státy, 34102
- Aqualane Clinical Research
-
New Port Richey, Florida, Spojené státy, 34652
- Suncoast Clinical Research
-
Orlando, Florida, Spojené státy, 32832
- Conquest Research
-
Tampa, Florida, Spojené státy, 33609
- Axiom Brain Health, LLC
-
Winter Park, Florida, Spojené státy, 32789
- Conquest Research
-
-
Georgia
-
Decatur, Georgia, Spojené státy, 30030
- Accel Neurosciences
-
Gainesville, Georgia, Spojené státy, 30501
- CARE (Center for Advanced Research & Education)
-
-
Hawaii
-
Honolulu, Hawaii, Spojené státy, 96817
- Hawaii Pacific Neuroscience
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60612
- Rush University Medical Center
-
Chicago, Illinois, Spojené státy, 60611
- Re:Cognition Chicago
-
Chicago, Illinois, Spojené státy, 60618
- Charter Research Chicago
-
Chicago, Illinois, Spojené státy, 60640
- Great Lakes Clinical Trials/Flourish Research
-
Springfield, Illinois, Spojené státy, 62702
- Southern Illinois University
-
-
Indiana
-
Indianaopolis, Indiana, Spojené státy, 46256
- JWM Research
-
-
Kansas
-
Wichita, Kansas, Spojené státy, 37214
- Ascension via Christi Research
-
-
Louisiana
-
Metairie, Louisiana, Spojené státy, 70006
- Tandem Intermediate
-
-
Maryland
-
Pikesville, Maryland, Spojené státy, 21208
- Headlands Research Pharmasite
-
-
Massachusetts
-
Foxborough, Massachusetts, Spojené státy, 02035
- Neurology Center of New England, PC
-
Plymouth, Massachusetts, Spojené státy, 02360
- Headlands Research Easter Massachusetts
-
Russells Mills, Massachusetts, Spojené státy, 02747
- Mayflower Clinical
-
Springfield, Massachusetts, Spojené státy, 01103
- Elixia MA
-
-
Michigan
-
Farmington Hills, Michigan, Spojené státy, 48334
- Quest Research Institute
-
-
Mississippi
-
Flowood, Mississippi, Spojené státy, 39232
- Precise Research Center
-
-
Missouri
-
Chesterfield, Missouri, Spojené státy, 63005
- Clinical Research Professionals - Headlands Research
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89121
- Oasis Clinical Trials LLC
-
-
New Jersey
-
Toms River, New Jersey, Spojené státy, 08755
- Cenexel Advanced Medical Research of New Jersey (AMRI)
-
West Long Branch, New Jersey, Spojené státy, 07764
- Advanced Clinical Institute
-
-
New York
-
Amherst, New York, Spojené státy, 14226
- Dent Neurologic Institute
-
Brooklyn, New York, Spojené státy, 11235
- SPRI
-
Lake Success, New York, Spojené státy, 11042
- Neurological Associates of Long Island
-
New York, New York, Spojené státy, 10003
- New York Neurology Associates
-
Staten Island, New York, Spojené státy, 10314
- Richmond Behavioral Associates
-
Syracuse, New York, Spojené státy, 13210
- Ichor Research
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27705
- Duke University
-
Matthews, North Carolina, Spojené státy, 28105
- AMC Research/Flourish Research
-
-
Ohio
-
Beavercreek, Ohio, Spojené státy, 45432
- American Clinical Research Center
-
Centerville, Ohio, Spojené státy, 45459
- Valley Medical Research
-
Independence, Ohio, Spojené státy, 44131
- Insight Clinical Trials
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97210
- Summit Headlands
-
-
Pennsylvania
-
Media, Pennsylvania, Spojené státy, 19063
- Suburban Research Associates
-
Plymouth Meeting, Pennsylvania, Spojené státy, 19462
- K2 Keystone
-
-
Rhode Island
-
East Providence, Rhode Island, Spojené státy, 02914
- Rhode Island Mood and Memory Research Institute
-
-
South Carolina
-
Summerville, South Carolina, Spojené státy, 29486
- Palmetto Primary Care & Specialty Physicians
-
-
Tennessee
-
Cordova, Tennessee, Spojené státy, 38018
- Neurology Clinic, P.C.
-
Nashville, Tennessee, Spojené státy, 37204
- K2 Medical Research Nashville
-
-
Texas
-
Austin, Texas, Spojené státy, 78757
- Senior Adults Specialty Research
-
Houston, Texas, Spojené státy, 77094
- NeuroMind Clinical Trials
-
Round Rock, Texas, Spojené státy, 78681
- Central Texas Neurology Associates
-
Wichita Falls, Texas, Spojené státy, 76309
- Grayline Research Center
-
-
Vermont
-
Bennington, Vermont, Spojené státy, 05201
- Memory Clinic, Inc.
-
-
Virginia
-
Arlington, Virginia, Spojené státy, 22205
- Sana Research
-
Fairfax, Virginia, Spojené státy, 22031
- Re:Cognition Fairfax
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.
-
Male or female, aged 55 - 85 years.
-
MMSE 20-28 at screening and baseline.
-
CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.
-
Positive for amyloid beta as defined by plasma p-tau217 level at screening.
-
Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.
-
Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.
-
Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:
-
Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
-
Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
-
Intrauterine device (IUD),
-
Intrauterine hormone-releasing system (IUS),
-
Bilateral tubal occlusion,
-
Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),
-
Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).
- Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
-
-
Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
- Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
- IUD,
- IUS,
- Bilateral tubal occlusion.
-
General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.
-
No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
-
Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.
- Cholinesterase inhibitors and/or memantine medication,
- Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
- Mood-stabilizing psychotropic agents including, but not limited to, lithium.
-
Adequate visual and hearing ability (physical ability to perform all the study assessments).
-
Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.
Exclusion Criteria:
-
Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.
-
History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).
-
Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.
-
Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.
-
Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.
-
Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).
-
Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.
-
Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
-
Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
-
Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
-
Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
-
Participants with learning disability or developmental delay.
-
Participants whom the PI deems to be otherwise ineligible.
-
Participants with a known allergy to the investigational drug or any of its components.
Inactive ingredients of the investigational medicinal product:
- Silicified Microcrystalline Cellulose
- Dibasic Calcium Phosphate Dihydrate
- Mannitol
- Stearic Acid
- Hypromellosee (capsule shells structure)
- Titanium dioxide (opacifier of the capsule shells)
-
Participant is currently pregnant, breast-feeding, and/or lactating.
-
Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.
-
Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Komparátor placeba: Placebo
|
Placebo capsule by mouth once daily for 18 months |
|
Experimentální: buntanetap
|
30mg capsule by mouth once daily for 18 months |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Časové okno: From screening to 6-month readout, to end of treatment at 18 months.
|
ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment. |
From screening to 6-month readout, to end of treatment at 18 months.
|
|
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Časové okno: From screening to 6-month readout, to end of treatment at 18 months.
|
The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function. |
From screening to 6-month readout, to end of treatment at 18 months.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- ANVS-25001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .